Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00411073 · ClinicalTrials.gov registry record · Phase 1
Study Of The Effects Of SB 480848 (Darapladib) On The Electrical Conduction Of The Heart
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT00411073 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 72 participants.
The verdict
NCT00411073, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
This is a study to assess the effects of darapladib on the cardiac conduction of the heart as compared to placebo and moxifloxacin. This a four period crossover design with each period lasting about 10 days. There will be a 7 to 10 day wash out in between each period.
Interventions
- DRUG Darapladib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2006-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00411073
The ClinicalTrials.gov registry entry for NCT00411073 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Darapladib is the first listed.
NCT00411073 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00411073 about?
NCT00411073 is a clinical study titled "Study Of The Effects Of SB 480848 (Darapladib) On The Electrical Conduction Of The Heart". This is a study to assess the effects of darapladib on the cardiac conduction of the heart as compared to placebo and moxifloxacin. This a four period crossover design with each period lasting about 10 days. There will be a 7 to 10 day wash out in between each period.
What is the current status of trial NCT00411073?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2006-12.
What interventions are being tested in trial NCT00411073?
The interventions under investigation include: Darapladib (DRUG).
Who is sponsoring clinical trial NCT00411073?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.